ESCAschool study: trial protocol of an adaptive treatment approach for school-age children with ADHD including two randomised trials by Döpfner, Manfred et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
ESCAschool study: trial protocol of an adaptive treatment approach for
school-age children with ADHD including two randomised trials
Döpfner, Manfred; Hautmann, Christopher; Dose, Christina; Banaschewski, Tobias; Becker, Katja;
Brandeis, Daniel; Holtmann, Martin; Jans, Thomas; Jenkner, Carolin; Millenet, Sabina; Renner,
Tobias; Romanos, Marcel; von Wirth, Elena
Abstract: BACKGROUND: The ESCAschool study addresses the treatment of school-age children with
attention-deficit/hyperactivity disorder (ADHD) in a large multicentre trial. It aims to investigate three
interrelated topics: (i) Clinical guidelines often recommend a stepped care approach, including differ-
ent treatment strategies for children with mild to moderate and severe ADHD symptoms, respectively.
However, this approach has not yet been empirically validated. (ii) Behavioural interventions and neu-
rofeedback have been shown to be effective, but the superiority of combined treatment approaches such
as medication plus behaviour therapy or medication plus neurofeedback compared to medication alone
remains questionable. (iii) Growing evidence indicates that telephone-assisted self-help interventions are
effective in the treatment of ADHD. However, larger randomised controlled trials (RCTs) are lacking.
This report presents the ESCAschool trial protocol. In an adaptive treatment design, two RCTs and
additional observational treatment arms are considered. METHODS: The target sample size of ES-
CAschool is 521 children with ADHD. Based on their baseline ADHD symptom severity, the children
will be assigned to one of two groups (mild to moderate symptom group and severe symptom group).
The adaptive design includes two treatment phases (Step 1 and Step 2). According to clinical guidelines,
different treatment protocols will be followed for the two severity groups. In the moderate group, the
efficacy of telephone-assisted self-help for parents and teachers will be tested against waitlist control in
Step 1 (RCT I). The severe group will receive pharmacotherapy combined with psychoeducation in Step
1. For both groups, treatment response will be determined after Step 1 treatment (no, partial or full
response). In severe group children demonstrating partial response to medication, in Step 2, the efficacy
of (1) counselling, (2) behaviour therapy and (3) neurofeedback will be tested (RCT II). All other treat-
ment arms in Step 2 (severe group: no or full response; moderate group: no, partial or full response)
are observational. DISCUSSION: The ESCAschool trial will provide evidence-based answers to several
important questions for clinical practice following a stepped care approach. The adaptive study design
will also provide new insights into the effects of additional treatments in children with partial response.
TRIAL REGISTRATION: German Clinical Trials Register (DRKS) DRKS00008973 . Registered 18
December 2015.
DOI: https://doi.org/10.1186/s12888-017-1433-9
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-141258
Published Version
 
 
Originally published at:
Döpfner, Manfred; Hautmann, Christopher; Dose, Christina; Banaschewski, Tobias; Becker, Katja; Bran-
deis, Daniel; Holtmann, Martin; Jans, Thomas; Jenkner, Carolin; Millenet, Sabina; Renner, Tobias;
Romanos, Marcel; von Wirth, Elena (2017). ESCAschool study: trial protocol of an adaptive treat-
ment approach for school-age children with ADHD including two randomised trials. BMC Psychiatry,
17(1):269.
DOI: https://doi.org/10.1186/s12888-017-1433-9
2
STUDY PROTOCOL Open Access
ESCAschool study: trial protocol of an
adaptive treatment approach for school-
age children with ADHD including two
randomised trials
Manfred Döpfner1,2*†, Christopher Hautmann1,2†, Christina Dose1, Tobias Banaschewski3, Katja Becker4,
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Abstract
Background: The ESCAschool study addresses the treatment of school-age children with attention-deficit/
hyperactivity disorder (ADHD) in a large multicentre trial. It aims to investigate three interrelated topics: (i) Clinical
guidelines often recommend a stepped care approach, including different treatment strategies for children with
mild to moderate and severe ADHD symptoms, respectively. However, this approach has not yet been empirically
validated. (ii) Behavioural interventions and neurofeedback have been shown to be effective, but the superiority of
combined treatment approaches such as medication plus behaviour therapy or medication plus neurofeedback
compared to medication alone remains questionable. (iii) Growing evidence indicates that telephone-assisted self-
help interventions are effective in the treatment of ADHD. However, larger randomised controlled trials (RCTs) are
lacking. This report presents the ESCAschool trial protocol. In an adaptive treatment design, two RCTs and
additional observational treatment arms are considered.
Methods: The target sample size of ESCAschool is 521 children with ADHD. Based on their baseline ADHD
symptom severity, the children will be assigned to one of two groups (mild to moderate symptom group and
severe symptom group). The adaptive design includes two treatment phases (Step 1 and Step 2). According to
clinical guidelines, different treatment protocols will be followed for the two severity groups. In the moderate
group, the efficacy of telephone-assisted self-help for parents and teachers will be tested against waitlist control in
Step 1 (RCT I). The severe group will receive pharmacotherapy combined with psychoeducation in Step 1. For both
groups, treatment response will be determined after Step 1 treatment (no, partial or full response). In severe group
children demonstrating partial response to medication, in Step 2, the efficacy of (1) counselling, (2) behaviour
therapy and (3) neurofeedback will be tested (RCT II). All other treatment arms in Step 2 (severe group: no or full
response; moderate group: no, partial or full response) are observational.
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Discussion: The ESCAschool trial will provide evidence-based answers to several important questions for clinical
practice following a stepped care approach. The adaptive study design will also provide new insights into the
effects of additional treatments in children with partial response.
Trial registration: German Clinical Trials Register (DRKS) DRKS00008973. Registered 18 December 2015.
Keywords: Attention-deficit/hyperactivity disorder, School-age children, Stepped care, Adaptive treatment, Self-help,
Pharmacotherapy, Behaviour therapy, Neurofeedback
Background
For the treatment of attention-deficit/hyperactivity dis-
order (ADHD), European and German clinical guidelines
recommend a stepped care approach with individualised
adaptive treatment strategies [1–3]. Depending on the se-
verity of symptoms (e.g. mild to moderate, severe), differ-
ent treatment protocols are recommended. Many studies
have demonstrated the efficacy of single treatment options
such as pharmacotherapy, behavioural interventions, neu-
rofeedback, and self-help for parents. However, there is lit-
tle knowledge about the efficacy of adaptive treatment
strategies combining these interventions in the treatment
process according to the patient’s needs.
Various randomised controlled clinical trials (RCTs)
have demonstrated the robust efficacy of both methyl-
phenidate and atomoxetine in the treatment of ADHD
in schoolchildren. Meta-analyses indicate that the effect
sizes of atomoxetine and other non-stimulant medica-
tions are significantly smaller than those of immediate-
release stimulants or long-acting stimulants [4, 5].
Several meta-analyses have analysed the efficacy of be-
havioural interventions including parent management
training and school-based interventions. For psycho-
social interventions, the analyses found moderate [6] to
large [7] effect sizes. Recent meta-analyses revealed ef-
fects on core ADHD symptoms in unblinded but not in
blinded ratings [8, 9]. However, the blinded ratings used
may not be valid for the assessment of the effects of par-
ent training at home. Moreover, a higher efficacy of
combined behavioural and pharmacological treatment
compared to pharmacotherapy alone remains question-
able [6, 10, 11]. This may be explained, at least in part,
by the high efficacy of pharmacotherapy. In patients
showing a strong treatment response to pharmacother-
apy, there is only little room for further improvement,
whereas in patients with a partial or no response to
medication, additional effects of psychotherapy or other
psychosocial interventions seem to be more likely.
Although pharmacotherapy and behaviour therapy are
established treatment options, they are intense, time-
consuming and may have side effects [12]. Waiting lists
for outpatient treatments are common in most European
countries, as there is an imbalance between the availabil-
ity of child psychiatric and psychotherapeutic services
and patients’ demand. Therefore, there is a need for
low-threshold therapeutic services that are easy to dis-
seminate. Reviews indicate growing evidence for the effi-
cacy of telephone-assisted self-help interventions for
parents of children with ADHD [13, 14]. However, there
is a lack of larger RCTs and of trials evaluating this
intervention as an initial low-threshold type of treatment
in patients with less severe ADHD symptoms. In a re-
cent study not covered by the aforementioned reviews,
telephone-assisted self-help for parents of 8–12-year-old
children with ADHD proved to be more effective than
treatment as usual [15]. Our own research has demon-
strated the effects of telephone-assisted self-help for par-
ents of preschool children with ADHD and other
externalising behaviour problems [16, 17]. Moreover, a
large observational study employing a self-help
programme for parents demonstrated symptom reduc-
tion in school-age children with ADHD [18], and a re-
cent study demonstrated additional effects of telephone-
assisted self-help on externalising symptoms in school-
age children with ADHD and persisting functional im-
pairment despite methylphenidate treatment [19]. A fur-
ther recent study indicated that both behaviourally
oriented and non-directive-oriented telephone-assisted
self-help interventions may be effective in the treatment
of externalising behaviour problems [20].
Neurofeedback has gained some empirical support
in recent years. Meta-analytic findings following a
rigorous methodological approach found small to
moderate significant treatment effects of neurofeed-
back on ADHD scores from unblinded informants [9,
21]. Although the effect of neurofeedback was non-
significant in blinded assessments and in trials with
active/sham controls, somewhat larger and significant
effects were found in the few studies using standard
neurofeedback protocols [21].
Adaptive interventions customize the individual treat-
ment during the therapy process to the patient’s needs
and responses to previous treatments. This may include
a change of the intensity of an already existing interven-
tion, a change of the type of intervention, or a combin-
ation of the previous treatment with other forms of
therapy. For the treatment of ADHD, adaptive interven-
tions have barely been investigated. Nevertheless, some
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growing interest over the years can be discerned [22–28].
For example, a study examining adaptive multimodal
treatment in children with ADHD detected additive ef-
fects of pharmacotherapy and psychotherapy in patients
who responded only partially to medication [23].
The primary objective of the study Evidence-Based,
Stepped Care of ADHD in School-Age Children Between
6 and 11 Years (ESCAschool) is to assess the efficacy of
a stepped care approach involving individually tailored
adaptive treatment strategies. The secondary objective is
to examine the predictability of treatment response by
psychological (e.g. child temperament, parental psycho-
pathology) and biological domains (e.g. electroencephal-
ography). Interventions included in the trial are (i)
telephone-assisted self-help for parents and teachers, (ii)
individual behaviour therapy, (iii) pharmacotherapy (plus
psychoeducation or counselling), and (iv) neurofeedback.
As recommended by European and German clinical
guidelines [1, 3], different treatment protocols will be
followed for children with mild to moderate versus se-
vere ADHD. For all patients and their families, the inter-
vention will be divided into two treatment periods (Step
1, Step 2), with treatment in Step 2 depending on the
patient’s response to the treatment in Step 1 (no, partial
and full response). This report presents the ESCAschool
trial protocol (version 4 from 22 December 2016) and
has been conceived under consideration of the SPIRIT
guidelines [29, 30].
ESCAschool is part of the research consortium ESCA-
life (http://www.esca-life.org/). The primary aim of the
umbrella project is to investigate adaptive interventions
for patients with ADHD from preschool age to adult-
hood. Besides ESCAschool, ESCAlife encompasses the
ESCApreschool study for preschool children aged 3 to
6 years, the ESCAadol study for adolescents aged 12 to
15 years and the ESCAlate study for adolescents and
adults aged 16 and 45 years.
Methods/design
Sites
This is a multisite trial with nine study centres located
in Germany (Cologne, Essen, Göttingen, Hamm, Mainz,
Mannheim, Marburg, Würzburg, Tübingen). If required,
additional centres will be included. The coordinating
centre is the Department of Child and Adolescent
Psychiatry, Psychosomatics and Psychotherapy, Medical
Faculty of the University of Cologne and has the main
responsibility for the trial protocol, the content and ex-
tent of the treatment as well as supervision. One excep-
tion is the treatment planning for neurofeedback which
is primarily organized by Hamm and Mannheim. In gen-
eral patients are treated locally at the respective study
centres with the exception of telephone-assisted self-
help for parents and teachers which is centrally provided
and exclusively conducted by Cologne. Responsibility for
monitoring, data management, biometry and project co-
ordination has the Clinical Trials Unit at the University
Medical Centre Freiburg.
Inclusion and exclusion criteria
Families have to meet the following inclusion criteria: (i)
child age 6;0 to 11;11 years; (ii) child attendance of
school (including special schools); (iii) child meeting cri-
teria for ADHD diagnosis according to the DSM-5 [31];
(iv) existence of informed consent of both parents or
guardians and assent of the child.
Exclusion criteria are: (i) child intelligence quotient
(IQ) below average (IQ < 80); (ii) child clinical diagnosis
of a pervasive developmental disorder, schizophrenia, bi-
polar disorder, severe depressive episode, epilepsy or
heart disease; (iii) insufficient German language or read-
ing skills of the parent with primary treatment involve-
ment; (iv) current or planned intensive behaviour
therapy for child ADHD or oppositional behaviour on a
weekly basis; (v) known non-response of the child to all
standard ADHD medication (methylphenidate, dexam-
phetamine, atomoxetine); (vi) psychotropic medication
of the child other than for the treatment of ADHD, or
neuroleptic medication other than for the treatment of
disturbances of impulse control.
Study design
The trial design is described in Fig. 1. Children who are
eligible for the study will be categorised into a group
with mild to moderate ADHD symptoms and a group
with severe symptoms based on a clinician-administered,
structured interview with the parent according to DSM-
5 criteria. Both groups will undergo two treatment
phases; the first (Step 1) will take 3 months (for waiting-
list patients with mild to moderate symptoms, this
period will last for 6 months) and the second (Step 2)
will last for 6 months.
For children with severe ADHD, Step 1 treatment will
comprise psychoeducation and ADHD medication treat-
ment (PE & MED; see Fig. 1). The interventions in Step
2 will be chosen depending on the response to the treat-
ment in Step 1. Step 1 full responders will receive con-
tinued medication plus counselling (Cont. MED &
Counselling). Partial responders will be randomised to
one of three treatment arms: (i) continued medication
plus counselling (Cont. MED & Counselling), which is
identical to the treatment of full responders, (ii) contin-
ued medication plus behaviour therapy (Cont. MED &
BT), or (iii) continued medication plus neurofeedback
(Cont. MED & NF). Step 1 non-responders will be re-
ferred to alternative pharmacotherapy according to treat-
ment guidelines and will additionally receive behaviour
therapy (MED Management & BT).
Döpfner et al. BMC Psychiatry  (2017) 17:269 Page 3 of 14
Families of children with mild to moderate ADHD
symptoms will be randomised in Step 1 either to
telephone-assisted self-help (TASH) for parents and
teachers or to a waitlist control group (Waiting Control;
see Fig. 1). Waiting Control families will receive
TASH after a 3-month waiting period (for these pa-
tients, Step 1 will last for 6 months). In Step 2, for
children with mild to moderate ADHD symptoms, the
following treatments will be delivered depending on
the response to the treatment in Step 1: Step 1 full
responders will receive booster sessions of telephone-
assisted self-help for parents and, if desired, for
teachers (Booster Self-Help). Step 1 partial responders
will receive behaviour therapy (BT) and Step 1 non-
responders will receive pharmacotherapy plus behav-
iour therapy (MED Management & BT).
Definition of symptom severity at baseline
At baseline, children will be assigned to one of two
ADHD symptom severity groups based on a clinical
rating: (a) a group with mild to moderate symptoms
and (b) a group with severe symptoms. Severe group
children have to meet both of the following criteria:
(i) a mean item score ≥ 2 (possible range 0–3) on the
inattentiveness scale and/or the hyperactivity/impul-
siveness scale of a clinician-administered, structured
interview assessing DSM-5 criteria for ADHD (Inter-
viewleitfaden mit Diagnose-Checkliste für Aufmerk-
samkeitsdefizit−/Hyperaktivitätsstörungen [DCL-
ADHS]) [32], (ii) a rating ≥ 5 on the severity scale
(range 1–7) of the Clinical Global Impressions (CGI)
[33]. All children who are eligible for the study, but
who do not meet these criteria, will be assigned to
the moderate group.
Definition of treatment response and expected response
rates
After Step 1, the treatment response of all children will
be determined by a clinical rating. Three response
groups will be distinguished: (a) patients showing full
treatment response, (b) patients showing partial treat-
ment response and (c) patients with no treatment
response.
Full responders have to fulfil all of the following cri-
teria: (i) mean item score ≤ 1 on the inattentiveness scale
of the DCL-ADHS; (ii) mean item score ≤ 1 on the
hyperactivity/impulsiveness scale of the DCL-ADHS; (iii)
CGI severity scale score < 3.
To be classified as a partial responder, a patient has to
fulfil the following criteria: (i) a reduction of the DCL-
ADHS total score by at least 20% compared to baseline;
(ii) a mean item score > 1 on the inattentiveness scale of
the DCL-ADHS or a mean item score > 1 on the hyper-
activity/impulsiveness scale of the DCL-ADHS or a
score ≥ 3 on the CGI severity scale. The second criterion
serves to indicate that there are still clinically meaningful
ADHD symptoms or a meaningful impairment in these
patients.
Non-responders are defined as follows: (i) Reduction
in DCL-ADHS total scale is less than 20% compared to
baseline. (ii) The second criterion for non-responders is
identical to criterion ii for partial responders.
It is hypothesised that 30% of the children in the se-
vere group will be full responders, 60% will be partial re-
sponders and 10% non-responders. These estimates are
Fig. 1 Study design of the ESCAschool study testing a stepped care approach and adaptive intervention strategies for children with ADHD
including different treatment protocols for children with mild to moderate symptoms and children with severe symptoms. The percentages in
the ovals for the response categories indicate expected response rates to the treatment in Step 1. T0 to T4 = assessment points;
R = randomisation; PE = psychoeducation; MED = ADHD medication treatment; TASH = telephone-assisted self-help for parents; BT = behaviour
therapy; NF = neurofeedback; SH = self-help; n = planned/estimated sample size
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derived from the response rates in trials on the efficacy
of pharmacotherapy [4, 5]. Based on previous trials on
self-help interventions for parents of children with
ADHD [13, 34], 30% of the patients in the moderate
group are estimated to be full responders, 40% to be par-
tial responders, and 30% to be non-responders.
Trial interventions
The intervention study is based on four major therapy
approaches: pharmacotherapy (plus psychoeducation or
counselling), behaviour therapy, neurofeedback,
telephone-assisted self-help. These interventions will be
offered either as single treatments or in combination.
Pharmacotherapy (plus psychoeducation or counselling)
Pharmacotherapy will be conducted by physicians of the
study centres or by local physicians with primary re-
sponsibility for child care. Practitioners will be advised
to follow treatment guidelines for pharmacotherapy of
ADHD, but there are no study-related restrictions re-
garding their choice of substance class or dosage. How-
ever, if Step 1 therapy starts with a first-line stimulant
medication that proves to be insufficient after titration
(e.g. immediate-release methylphenidate), practitioners
will be asked to reconsider another stimulant medication
for Step 1 treatment (e.g. sustained-release methylphen-
idate, dexamfetamine, lisdexamfetamine) and to preserve
a change in the drug class to Step 2 treatment (e.g. non-
stimulant) if this procedure is medically acceptable.
For pharmacological treatment, the number of visits
will depend on the patient’s individual needs (about
three visits planned in Step 1 and about four in Step 2).
For psychoeducation or counselling, four additional ses-
sions are scheduled.
Behaviour therapy
Individually tailored behaviour therapy will encompass
(i) parent management training, including parent-child
interaction training, (ii) child-focused interventions, es-
pecially organisational skills training, (iii) teacher-
focused interventions, including psychoeducation and
behavioural interventions at school. Twenty sessions are
planned on a weekly basis. The treatment is primarily
based on the German treatment manual Therapiepro-
gramm für Kinder mit hyperkinetischem und oppositio-
nellem Problemverhalten (THOP), which includes
parent-, child- and teacher-focused interventions [35].
The efficacy of this intervention has been demonstrated
in several clinical trials [23, 24, 27, 36, 37]. In addition,
child-focused organisational and planning skills training
interventions based on the German Therapieprogramm
zur Steigerung von Organisationsfähigkeit, Konzentration
und Impulskontrolle bei Kindern mit ADHS (THOKI-
ADHS) will be included [38]. This manual describes
interventions evaluated by Abikoff et al. [39] and Lang-
berg et al. [40]. For each patient, an individual treatment
plan will be established together with the supervisor
after the fifth treatment session. The treatment will be
conducted by clinical therapists who will be trained in
the specific interventions in a two-day workshop.
Neurofeedback
Neurofeedback will be conducted following a slightly
modified protocol of a previous controlled study [41]. In
ESCAschool, participants will receive 25 sessions of neu-
rofeedback of slow cortical potentials (SCPs). Each session
will last for approximately 60 min, including time needed
for electrode montage as well as four 10-min blocks of
feedback. Each block consists of 40 trials and each trial is
composed of a baseline phase (2 s) and a feedback phase
(8 s). If patients are successful for at least 2 s in total dur-
ing the second half of the feedback phase, a sun is shown
as positive reinforcement. The training protocol prompts
either negative potential or positive potential shifts com-
pared to the baseline [42]. Within the first 12 training ses-
sions, negativity and positivity are trained in randomised
succession in a 50:50 ratio. The ratio is changed to 60:40
within the last 13 sessions. During each session, feedback
is given in blocks 1 and 3. To enable the transfer of self-
regulation skills to everyday life, participants perform the
second and fourth blocks of each session without continu-
ous feedback (transfer trials). Participants are able to earn
a certain amount of tokens for taking part and good co-
operation. To strengthen the transfer, every session is
followed by a short transfer exercise before doing some
homework in the lab.
Electroencephalography (EEG) is recorded and fed
back with a multichannel amplifier (THERA PRAX®,
neuroConn GmbH, Ilmenau, Germany). The EEG elec-
trode is placed at Cz, referenced against the mastoid be-
hind the right ear. Four electrodes are used to record
the vertical and horizontal electrooculogram (EOG) and
one electrode behind the right ear is used as ground.
Each study centre will be guided by a detailed manual to
ensure equal handling of participants and devices.
Telephone-assisted self-help
The behaviour therapy-oriented telephone-assisted self-
help programme will address both the parents and the
teachers of the children. It consists of self-help booklets
on ADHD and behaviour modification techniques plus
additional telephone consultations. The parents and
teachers will receive the booklets by mail and will be
asked to read them and to implement the interventions
described therein. Furthermore, the telephone consulta-
tions will serve to help the parents or teachers to apply
the interventions to the child’s specific problem behav-
iours. The parent programme includes eight booklets
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[43] and ten 20–30-min telephone consultations carried
out approximately once a week. The booklets for parents
are revised versions of booklets used in earlier trials,
which have already demonstrated the efficacy of
telephone-assisted self-help [16, 17, 19, 20], and deal
with the following issues: (a) definition of individual
problem behaviours of the child which the parents wish
to address during the intervention, (b) psychoeducation
about ADHD including information about the aetiology
of ADHD, comorbidities, and different treatment op-
tions, (c) encouragement of positive parent-child interac-
tions, (d) implementation of family rules, (e) effective
commands and appropriate positive consequences for
following rules, (f ) appropriate negative consequences
for breaking rules, (g) reward systems, and (h) develop-
ment of a daily structure, leisure activities of the child
(e.g. use of media), and stress reduction techniques for
parents. The teacher programme is composed of four
self-help booklets [44] and four telephone consultations
of up to 60 min each. The contents of the booklets are
similar to those of the parent booklets, but some sec-
tions are modified to fit better to the school environ-
ment. The participation of the teacher is optional; only if
both the parents and the teacher agree to participation
the teacher will be contacted.
If children are full responders to the three-month self-
help intervention in Step 1, two additional telephone
consultations for the parents and, where appropriate,
one additional telephone consultation for the teacher
will be provided (Booster Self-Help).
Treatment fidelity
Treatment fidelity will be assured by (i) training in man-
ualised treatment procedures (except pharmacotherapy),
(ii) a structured protocol completed by therapists after
each session, and (iii) supervision of behaviour therapy
and telephone-assisted self-help by senior supervisors,
either face-to-face or by telephone. Behaviour therapies
will be supervised after treatment sessions 5, 10 and 15,
including a review of at least two videotaped sessions.
Supervision for self-help will be scheduled on a weekly
basis and may comprise audiotaped telephone calls
whenever required.
Informants
The following informants will be considered for assess-
ment: unblinded clinician, blinded clinician, parent, part-
ner, and teacher. The unblinded clinician is a member of
the project staff, is involved in diagnostics or in therapy
and may be aware of the treatment condition and the
time of the assessment, although efforts are taken to
blind the raters. The blinded clinician is also a member
of the project staff, is involved only in diagnostics and is
aware of neither the treatment condition nor the time of
the assessment. His or her rating is based on videotaped
records of parent interviews conducted by the unblinded
clinician. The parent may be the biological parent or the
guardian of the child and is involved in the treatment.
The partner is the second parent or guardian and is gen-
erally not primarily involved in the treatment (only com-
pletes the baseline assessment T1). The teacher is the
child’s schoolteacher, preferably the class teacher with
the main responsibility for the child’s school routine.
Measurements – Main assessment points and therapy
process data
During the trial, data will be collected (a) at several main
assessment points before and after the interventions as
well as (b) during the therapy process. The main assess-
ment points (T0/T1, T2, T3, T4) will take place accord-
ing to a specified schedule (see Fig. 1). The first two
measurements (T0/T1) serve to check the inclusion and
exclusion criteria and to collect baseline data. The third
measurement (T2) will take place after Step 1 treatment
(note that there are two T2 assessments for families ran-
domised to Waiting Control in the moderate group: one
after the three-month waiting period and one after the
telephone-assisted self-help which they receive after-
wards; see Fig. 1). The fourth measurement (T3) will be
conducted immediately after Step 2 treatment. The
follow-up measurement (T4) will occur three months
after the end of Step 2 treatment. In addition to the
main assessment points, the physicians and therapists
who conduct the intervention will provide ratings during
the therapy process after each session (e.g., adherence
and integrity).
Primary and secondary outcomes
Unless otherwise stated, all primary and secondary out-
come measures will be assessed at all main assessment
points (T0/T1, T2, T3, T4).
Primary outcome – Blinded clinician
The primary outcome is the blinded clinician-rated
ADHD score assessed by the total scale (18 items) of the
German Diagnose-Checkliste für Aufmerksamkeitsdefizit
−/Hyperaktivitätsstörungen (DCL-ADHS) based on the
German structured interview Interviewleitfaden für
Externale Störungen (ILF-EXTERNAL) conducted with
the parent [32]. The items reflect the criteria for ADHD
according to the DSM-5 and ICD-10 [45].
Secondary outcomes – Blinded clinician
Impairment due to ADHD symptoms will be rated on
the respective scale (5 items) of the DCL-ADHS. The
German Diagnose-Checkliste für Störungen des Sozialver-
haltens (DCL-SSV) serves to assess symptoms of oppos-
itional defiant disorder (ODD; 8 items), symptoms of
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disruptive mood dysregulation disorder (DMDD; 2
items), core symptoms of conduct disorder (CD; 7
items), characteristics of limited prosocial emotions (11
items) and impairment due to disruptive behaviour
problems (5 items) according to the ICD-10 and DSM-5
[32]. The DCL-SSV is based on ILF-EXTERNAL
conducted with the parent. A further secondary outcome
rated by the blinded clinician is the severity scale (1 item)
of the Clinical Global Impressions (CGI) [33].
Secondary outcomes – Unblinded clinician
All instruments available in blinded clinical rating
(DCL-ADHS, DCL-SSV and CGI severity) will have been
previously rated and videotaped by the unblinded clin-
ician involved in assessment. In addition, the unblinded
clinician will complete the improvement scale (1 item)
of the CGI and rate adherence to medication (if applic-
able), psychological side effects of the therapy (6 self-
developed items; assessed at T2 and T3) and additional
professional interventions received by the families be-
sides the study treatment (assessed at T2, T3 and T4).
Furthermore, therapists will rate their treatment satisfac-
tion (8 self-developed items; assessed at T2 and T3).
Secondary outcomes – Parent
The parent will complete the German Fremdbeurtei-
lungsbogen für Aufmerksamkeitsdefizit−/Hyperaktivität-
störungen (FBB-ADHS), which assesses ADHD
symptoms (18 items) and related impairment (5 items)
[32] as well as the German Fremdbeurteilungsbogen für
Störungen des Sozialverhaltens (FBB-SSV), which cap-
tures ODD symptoms (8 items), DMDD symptoms (3
items), CD symptoms (6 items), characteristics of limited
prosocial emotions (11 items), and impairment due to
disruptive behaviour problems (5 items) [32]. The FBB-
ADHS and FBB-SSV both consider criteria according to
the DSM-5 and ICD-10. Further measures are the in-
ternalizing problems scale (32 items) of the German
translation of the Child Behavior Checklist for Ages 6–18
(CBCL/6–18R) [46, 47], the German version of the
Weiss Functional Impairment Rating Scale – Parent Re-
port (WFIRS-P) [48, 49], which measures functional im-
pairment, and the KIDSCREEN-10 Index [50] to assess
child quality of life (10 items). Parenting-related mea-
sures comprise the total scale (27 items) of the German
questionnaire Verhalten in Risikosituationen (VER) to
assess the perceived ability to solve difficult parenting
situations [51], the total scale (13 items) of the German
questionnaire Fragen zum Erziehungsverhalten (FZEV)
to measure positive, reinforcing and promotive parenting
practices [51], and a short version of the negative scale
(13 items) of the German Fragebogen zum positiven und
negativen Erziehungsverhalten (FPNE) to assess dysfunc-
tional parenting practices [52]. Satisfaction with Step 1
treatment (8 self-developed items) will be assessed at T2
and satisfaction with Step 2 treatment at T3.
Secondary outcomes – Teacher
Teachers will rate the same items of the FBB-ADHS and
FBB-SSV as those rated by the parent.
Secondary outcome – Biological
For a subgroup of children, EEG will be measured before
and immediately after Step 2 treatment (T2 and T3).
EEG will only be measured in children who receive neu-
rofeedback or behaviour therapy as part of the treatment
in Step 2. EEG outcome parameters are the resting theta
activity (hypothesised reduction) and the contingent
negative variation (CNV) amplitude (hypothesised
increase).
Predictors of treatment response
The secondary objective of the ESCAschool study is the
prediction of treatment response. This concerns variables
assessed prior to Step 1 (T0/T1) and Step 2 treatment
(T2) as well as therapy process data (Step 1, Step 2).
Predictors – Psychological data
Psychological data will be collected from (a) the un-
blinded clinician, (b) the parent, (c) the partner, and (d)
in the form of test diagnostics.
Unblinded clinician The following variables will be
assessed by a clinical interview with the parent during
diagnostic assessment at T0/T1: sociodemographic data of
the child and the parent (e.g. child age, education of the
parent or guardian), early child development (6 self-
developed items) and temperament (13 self-developed
items), life events (14 self-developed items), and the Fam-
ily Adversity Index (FAI) adopted from the German Man-
nheimer Elterninterview [53]. The clinical checklist
Diagnose-Checkliste zum Screening psychischer Störungen
(DCL-SCREEN) will be applied to assess comorbid symp-
toms of depression (7 items), autism (4 items), anxiety (10
items), other neurodevelopmental disorders (6 items),
obsessive-compulsive disorder (2 items) and tic disorders
(1 item) [32]. Based on a modified questionnaire by
Piacentini et al. [54], the therapists will additionally report
their expectation of treatment benefit (3 items) for a fam-
ily assigned to a particular treatment arm (rated at T0/T1
before Step 1 treatment and at T2 before Step 2 treat-
ment). Furthermore, every therapy session of Step 1 and
Step 2 treatment will be rated with respect to treatment
integrity (13 self-developed items), treatment adherence of
the client (10 items; for TASH only 8 items), and current
ADHD symptoms of the child (4 items; shortened version
of the German ADHS-Bogen) [55].
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Parent The following domains will be assessed by ratings
of parents at T0/T1: child irritability (7 items) by the
Affective Reactivity Index (ARI) [56], child personality
(novelty seeking, harm avoidance, reward dependence,
persistence, self-directedness, cooperativeness, self-
transcendence) by the German Junior Temperament und
Charakter Inventar [57] in the version for children aged 7
to 11 years (JTCI 7–11 R; 86 items), severity of social defi-
cits in the autism spectrum by a short version (16 items)
of the German translation of the Social Responsiveness
Scale (SRS) [58–60]. Moreover, parents will complete the
anger control scale of the German Elternfragebogen zum
Umgang mit Ärger (FB-Ä) [61], which is a modified ver-
sion of the 12-item form of the Aggression Questionnaire
[62, 63] to measure parental aggression. Depression, anx-
iety and stress will be assessed by the German 21-item
version [64, 65] of the Depression Anxiety Stress Scales
(DASS) [66] and parental ADHD by the German ADHS
Selbstbeurteilungsskala (ADHS-SB) [67], which was
adapted to the DSM-5 for use in this study.
Partner The parent with no primary involvement into
the treatment will complete the FB-Ä to assess parental
aggression and the ADHS-SB to measure parental
ADHD at the beginning of the study (T0/T1).
Test diagnostics At the beginning of the study (T0/T1),
the following test diagnostics will be applied: IQ will be
assessed using the total score of the German translation
of the Wechsler Nonverbal Scale of Ability [68, 69]. Fur-
ther neuropsychological testing will encompass a variant
of the Continuous Performance Task (CPT-OX) [70] to
assess sustained and selective attention. A modified ver-
sion of the Monetary Incentive Delay (MID) task [71,
72] will be used to investigate reward anticipation and
reward feedback, and a Stop-Signal Task (SST) [72, 73]
will be conducted to study inhibitory control. For chil-
dren receiving ADHD-related pharmacotherapy prior to
the start of the study, IQ will be tested under medication
and neuropsychological testing will be conducted with-
out medication.
Predictors – Biological data
The following imaging methods will be used to assess
biological predictors of treatment response in a sub-
project called ESCAbrain: EEG, magnetic resonance
imaging (MRI) and transcranial sonography (TCS).
TCS will be conducted in all patients and is not for-
mally bound to any of the main assessment points
(T0/T1 to T4). EEG and MRI are limited to patients
who receive neurofeedback or behaviour therapy as
part of their treatment in Step 2 (see Fig. 1). MRI as-
sessments will be conducted prior to the beginning of
Step 2 treatment (T2), whereas EEG assessments will
be performed prior to and after Step 2 treatments.
Furthermore, blood samples (and/or buccal swabs)
will be collected before Step 1 (T0/T1) and after Step
2 treatment (T3) to determine predictive genetic and
epigenetic patterns.
EEG The EEG-based predictors consist of the frequency
profile at rest (spontaneous theta band and alpha band
activity) and the strength of preparatory cognitive activ-
ity (CNV amplitude) measured during a cued continuous
performance task (CPT), which represent promising bio-
logical markers of ADHD and have been shown to ex-
plain nearly 30% of the variability in behavioural
improvement following neurofeedback treatment [74].
MRI The MRI-based predictors consist of the integrity
(fractional anisotropy) of the fronto-striatal connection,
and of volumetric grey matter density of the implicated
dorsolateral-prefrontal and striatal regions, which also
represent promising biological ADHD markers [75, 76].
TCS The TCS-based predictor is the extent of the echo-
genic region of the substantia nigra and has been identi-
fied as a potential biological ADHD marker [77].
Planned sample size and power calculations
Based on power calculations, 521 children have to be in-
cluded in the study. The entire stepped care design is
primarily powered for the two included RCTs. RCT I
concerns the moderate group, with randomisation for
Step 1 treatment, while RCT II addresses partial re-
sponders of the severe group, with randomisation for
Step 2 treatment.
For partial responders of the severe group, an effect
size of Cohen’s d = 0.6 is hypothesised regarding the
comparison of Cont. MED & Counselling (control) with
Cont. MED & BT, and also for the comparison of Cont.
MED & Counselling with Cont. MED & NF. With 59
patients per arm available for assessment after Step 2
treatment (T3), a one-way analysis of variance to com-
pare all three arms at a significance level of 5% will have
92% power (software: NQuery Advisor Version 7.0), and
a two-sided t-test at a significance level of 5% will have
89.8% power (software: STPLAN Version 4.3) for two-
arm comparisons to detect a difference when the true ef-
fect size is d = 0.6. Hence, a closed testing procedure
comparing two arms only if significant differences are
detected between the three arms will yield at least 82.6%
power for the two-arm comparisons of interventions to
control. To account for the possibility that about 10% of
patients will have incomplete data for the assessment
after Step 2 treatment (T3), in total, 198 partial re-
sponders should be randomised after T2 assessment for
Step 2 treatment. Assuming that 60% of the patients are
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partial responders after Step 1 treatment (T2), and 10%
of patients drop out from baseline (T0/T1) to T2, about
377 patients with severe ADHD will have to be included
at T0/T1 in order to achieve the target number of 198
randomisations.
Regarding treatment arms with randomisation in the
moderate group, for the comparison of TASH with
Waiting Control, an effect size of d = 0.5 is expected.
Using a two-sided t-test with a power of 80% at a signifi-
cance level of 5%, 64 patients with non-missing data per
group are required to detect a difference when the true
effect size is d = 0.5. Assuming that 10% of the families
will have incomplete data for the assessment after Step 1
treatment (T2), in total, 144 patients with moderate
ADHD should be randomised after T0/T1 assessment
for Step 1.
Compliance and rate of loss to follow-up
In our own pharmacotherapeutic trials as well as the tri-
als on self-help and those on behaviour therapy or neu-
rofeedback with similar treatment durations, losses to
follow-up were in the range of 6 to 10% [17, 23, 34, 78].
Statistical analysis
The primary statistical analyses will be intention-to-treat
analyses; that is, all randomised patients will be analysed
according to their allocated arms irrespective of whether
they refused or discontinued the treatment or whether
other protocol violations are revealed.
For the moderate group, the difference between TASH
and Waiting Control at T2 and in the severe group for
partial responders the difference between the three ran-
domised treatments in Step 2 at T3 will be evaluated in
separate linear regression models including treatment,
centre, and the respective baseline value as predictors.
Further covariates predictive of missingness will be in-
cluded based on a pre-specified selection strategy to cor-
rect for potential bias arising from missing data. Under
the assumption of missing at random (MAR), a complete
case analysis will be performed. As sensitivity analysis, a
worst-case analysis will be performed, assigning the best
possible outcome to missing values in the control group
and the worst possible outcome to those in the experi-
mental group(s). If this extreme analysis is still
favourable, then it can be confidently concluded that the
results are robust to the handling of missing data. The
significance test for the primary treatment comparison
in the moderate group will be based on least-squares
means and will be presented with two-sided 95% confi-
dence intervals. For the severe group, a closed test pro-
cedure will be applied: First, the null-hypothesis of equal
means in the three arms will be tested at a significance
level of 5%. If it can be rejected, the three pairwise treat-
ment comparisons will be carried out based on two-
sided 95% confidence intervals. This multiple test pro-
cedure assures control of the multiple type I error rate
of 5%.
Besides the primary statistical investigation, several
secondary analyses will be conducted. These include the
analysis of change during Step 1 and Step 2 treatment
separately for all study arms. Further, for certain sub-
groups, within-group comparisons will be conducted
and change during Step 1 will be contrasted with change
during Step 2 (i.e., test whether change during Step 1
and Step 2 differs for a particular subgroup). These
within-group comparisons concern full responders and
non-responders in the severe group as well as all re-
sponse types of the moderate group. Finally, predictors
and moderators of treatment response will be analysed
[79].
Patient registration and randomisation
Patients will be centrally registered at the Clinical Trials
Unit Freiburg. To guarantee concealment, central ran-
domisation at Step 1 and Step 2 will be performed. Ran-
domisation forms that are completed at the study
centres will be sent by fax to the Clinical Trials Unit
Freiburg. The study centre will be subsequently in-
formed about the randomised treatment arm by fax. If
the details on the randomisation fax appear to be incom-
plete or implausible, the Clinical Trials Unit Freiburg
will send a query fax to the investigator for clarification.
The randomization code will be generated by the
Clinical Trials Unit Freiburg to ensure that treatment as-
signment is unbiased and concealed from patients and in-
vestigator staff. Randomization will be performed in
blocks of variable length in a ratio of 1:1. The block
lengths will be documented separately and will not be dis-
closed to the center. The randomization code will be pro-
duced by validated programs based on the statistical
analysis system.
Data protection
Data will be entered and processed as soon as the signed
informed consent is available. All data relevant for the
trial will be typed into an electronic remote data entry
system (RDE-LIGHT) from all centres. The Clinical Tri-
als Unit Freiburg will provide the data entry system. Pa-
tient data will be registered pseudonymously. RDE-
LIGHT uses built-in security features to encrypt all data
for transmission in both directions, preventing un-
authorised access to confidential participant information.
Access to the system will be controlled by individually
assigned user identification codes and passwords, made
available only to authorised personnel.
Each patient will be identified with a study-specific
patient number, which will be allocated as soon as the
patient is included in the study. The patient number
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includes information about the centre (centre-specific
numbers will be allocated before trial start) as well as a
patient-specific number.
The Clinical Trials Unit Freiburg will process data
through personnel specifically trained for the study, who
will work according to the standard operating proce-
dures of the study centres. Legal regulations for data
protection will be fulfilled.
Data monitoring
Monitoring is performed by the Clinical Trial Unit Frei-
burg. The study centres will undergo monitoring visits
before, during and after the clinical trial. Prior to the
trial, a pre-trial visit by phone and face-to-face group
trainings are conducted in order to introduce the study
centres and to train staff members in the implementa-
tion of treatments and clinical interviews. During the
trial, the monitor will visit the site regularly depending
on the recruitment rate and quality of the data. Details
about the procedures are provided in a monitoring
manual.
Stopping rules
Stopping rules for an individual patient
One (or more) of the following circumstances will result
in an early study termination of single subjects (these
trial subjects will be rated as drop-out): (i) withdrawal of
informed consent of parents/guardians, (ii) withdrawal
of assent of the patient, (iii) unwillingness to further par-
ticipate in the trial, (iv) need for inpatient treatment or
other reasons affecting the patient’s well-being in the
case of continued trial participation, (v) need for a differ-
ent kind of treatment for health reasons according to
the judgement of the attending physician.
Global stopping rules
One (or more) of the following circumstances will result
in an early termination of the entire trial or in the clos-
ing of a single centre: (i) emergence of data leading to a
revision of the risk-benefit ratio. (ii) Participating centres
will be closed in the case of ongoing failure of recruit-
ment or repeated violations of the study protocol or of
standard good clinical practice rules.
However, prior to closing a centre, in the case of fall-
ing below the expected recruitment rate, compensation
by existing centres is intended (if necessary, new study
centres will be opened). Agreement between principal
investigator, site investigators, responsible ethics com-
mittee and the Clinical Trials Unit Freiburg is intended.
Legal and ethical foundation
Before trial start, all relevant documents have been sub-
mitted to the ethics committee responsible for the re-
spective participating centre. The primary vote of the
study has been obtained from the ethics committee of
the medical faculty of the University of Cologne.
All relevant changes to the trial protocol have to be re-
ported to the ethics committee. For changes to the trial
protocol that are formal in nature and include relevant
changes for trial subjects, the ethics committee has to
vote anew. Patients/trial subjects will have to be in-
formed about changes in the conditions of the study if
necessary. The ethics committee will have to be in-
formed immediately about complications and severe ad-
verse events during the project.
Risk-benefit considerations
The essential study-related procedures will take place in
routine care or complement routine care. The outpatient
unit will ensure the availability of professional counsel-
ling (including treatment recommendations) even if the
patient does not participate in the study.
The efficacy of the guided self-help intervention for
participants in the moderate group (Step 1) has been
confirmed in several studies. A waiting time of 3 months
is justifiable compared to the usual waiting time for
treatment in routine care. Waiting Control will receive
the guided self-help intervention after the waiting
period.
There are no known risks for the guided self-help
intervention, behaviour therapy, or neurofeedback. Pos-
sible side effects of the pharmacological treatment have
been investigated intensively and will be monitored in
regular patient contacts. Medication will be administered
in routine care.
Patients might be able to draw direct personal benefit
from participation in the study (e.g. through a more in-
tensive support) and future patients might benefit
through the incorporation of the study results into
guideline recommendations. Thus, treatment recom-
mendations will be more valid. Overall, the benefits of
the study exceed any possible risks.
Discussion
Clinical guidelines recommend a stepped care approach
with an individualised adaptive treatment. However, this
approach has not yet been empirically validated. The
main goal of the ESCAschool study is to assess the effi-
cacy of a stepped care approach in children with ADHD
aged 6 to 11 years and to investigate predictors of treat-
ment outcome. Different stepped care strategies for chil-
dren with mild to moderate versus severe ADHD will be
investigated.
Two RCTs are implemented in the design to assess the
efficacy of interventions at crucial points during the
therapy process. The first RCT concerns the efficacy of
telephone-assisted self-help for parents and teachers and
will be performed in children with mild to moderate
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ADHD, since there is a lack of trials evaluating this
intervention as an initial low-threshold type of treatment
in patients with less severe ADHD symptoms.
The additional effects of behaviour therapy and neuro-
feedback in patients with severe ADHD and with partial
response to medication will be evaluated in the second
RCT, because the supplementary effects of these inter-
ventions have not yet been sufficiently investigated for
this particular subgroup of patients. The aim is to inves-
tigate in more detail which treatment approach is best
suited for children who are already treated with medica-
tion but still show scope for symptom improvement.
The results will provide information about the treat-
ment of school-age children with ADHD and will help
to develop usable, potentially more cost-effective, indivi-
dualised stepped care approaches. The evaluation of pre-
dictors of treatment response will help to identify
indications for treatments.
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